Compare ECVT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECVT | DBVT |
|---|---|---|
| Founded | 1935 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2017 | 2014 |
| Metric | ECVT | DBVT |
|---|---|---|
| Price | $11.99 | $19.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $13.60 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 2.2M | 233.8K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,515,000.00 | $4,151,000.00 |
| Revenue This Year | $27.44 | $65.50 |
| Revenue Next Year | $5.65 | $47.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.70 | N/A |
| 52 Week Low | $5.24 | $3.91 |
| 52 Week High | $12.38 | $26.19 |
| Indicator | ECVT | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 60.25 | 44.76 |
| Support Level | $8.04 | $19.83 |
| Resistance Level | $12.33 | $24.47 |
| Average True Range (ATR) | 0.39 | 1.34 |
| MACD | 0.03 | -0.29 |
| Stochastic Oscillator | 75.62 | 24.63 |
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: Ecoservices and Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.